12th Sep 2016 08:37
LONDON (Alliance News) - NetScientific PLC on Monday said its portfolio company Glycotest has been granted a Japanese patent for its core technology for early detection of liver disease.
Glycotest now holds a total of six patents in Australia, the US and Japan, covering the use of over 50 glycoprotein biomarkers for the diagnosis of liver cancers and other liver diseases.
"We are delighted that the Japanese patent can now be added to Glycotest's rising number of patents which add to the breadth of the IP for its liver disease diagnostic platform. These granted patents and additional pending applications put Glycotest in a strong position to further protect its proprietary technology as it continues to grow," NetScientific Chief Executive Francois Martelet said in a statement.
Shares in NetScientific were trading up 3.5% at 75.00 pence on Monday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific